Abiopharma

Incyte gibt FDA-Zulassung für Monjuvi® (Tafasitamab-cxix) in Kombination mit Rituximab und Lenalidomid für Patienten mit rezidiviertem oder refraktärem follikulärem Lymphom bekannt

FDA approve ZIDOVUDINE

FDA approve AMLODIPINE BESYLATE

FDA approve L-GLUTAMINE

FDA approve ETHINYL ESTRADIOL; LEVONORGESTREL

FDA approve DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

FDA approve DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

FDA approve TOLTERODINE TARTRATE

FDA approve SPIRONOLACTONE

FDA approve DAPSONE

FDA approve ARGATROBAN

FDA approve ACETAZOLAMIDE SODIUM

FDA approve CLONIDINE

FDA approve COLCHICINE

RCKT INVESTOR NOTICE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit